AbbVie Gets FDA Nod for SKINVIVE, Positive CLL Trial Results

AbbVie (NYSE:ABBV) announced that the U.S. FDA has approved SKINVIVE by JUVÉDERM for reducing neck lines and improving neck appearance. Additionally, the company reported positive Phase 3 results for a venetoclax-based combination in previously untreated chronic lymphocytic leukemia (CLL) in less-fit patients.

The Product

SKINVIVE is a new addition to the JUVÉDERM line of dermal fillers, specifically designed to improve the appearance of the neck by reducing horizontal lines and enhancing skin elasticity. It is based on hyaluronic acid, a naturally occurring substance in the body.

Pricing and Availability

AbbVie has not yet disclosed pricing or availability for SKINVIVE. It is expected to be available by prescription from dermatologists and aesthetic practitioners.

Competition

SKINVIVE enters a competitive market that includes products like Botox and Dysport for neck wrinkles, as well as other hyaluronic acid fillers. However, SKINVIVE is the first FDA-approved product specifically for improving neck appearance.

Potential Impact on the Company

SKINVIVE strengthens AbbVie's medical aesthetics portfolio, which is a fast-growing segment. The product is expected to boost revenues in the aesthetics division. Meanwhile, the positive CLL results reinforce AbbVie's oncology pipeline, offering a new treatment option for patients unfit for intensive chemotherapy.